In vivo activity of oritavancin in animal infection models and rationale for a new dosing regimen in humans

Clinical Infectious Diseases

Volumn 54, Issue SUPPL. 3, 2012, Pages

  Ambrose, Paul G ^a,b   Drusano, George L ^c   Craig, William A ^d  

^a INSTITUTE FOR CLINICAL PHARMACODYNAMICS   (United States)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c ORDWAY RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEPHALOSPORIN; DAPTOMYCIN; NAFCILLIN; ORITAVANCIN; PENICILLIN G; VANCOMYCIN;

ANIMAL EXPERIMENT; ANTHRAX; ANTIBACTERIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL ENDOCARDITIS; BACTERIAL PNEUMONIA; BACTERIAL STRAIN; CATHETER INFECTION; CENTRAL VENOUS CATHETER; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; ENTEROCOCCUS; HAMSTER; HUMAN; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NEUTROPENIA; NONHUMAN; PHARMACODYNAMICS; PNEUMOCOCCAL MENINGITIS; PRIORITY JOURNAL; RABBIT; SIMULATION; SINGLE DRUG DOSE; STAPHYLOCOCCUS;

ANIMALS; ANTI-BACTERIAL AGENTS; CRICETINAE; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; GLYCOPEPTIDES; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MICE; RABBITS; RATS;

EID: 84859068650     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis001     Document Type: Article

References (36)

1. Jones RN, Barrett MS, Erwin ME. In vitro activity and spectrum of LY 333328, a novel glycopeptide derivative. Antimicrob Agents Chemother 1997; 41:488-93.
2. Schwalbe RS, MacIntosh AC, Qaiyumi S, et al. In vitro activity of LY333328, an investigational glycopeptide antibiotic, against enterococci and staphylococci. Antimicrob Agents Chemother 1996; 40:2416-9.
3. Zelenitsky SA, Karlowsky JA, Zhanel GG, Hoban DJ, Nicas T. Time-kill curves for a semisynthetic glycopeptide, LY 333328, against vancomycin- susceptible and vancomycin-resistant Enterococcus faecium. Antimicrob Agents Chemother 1997; 41:1407-8.
4. Fasola E, Spangler SK, Ednie LM, Jacobs MR, Bajaksouzian S, Applebaum PC. Comparative activities of LY 333328, a new glycopeptide, against penicillin-susceptible and-resistant pneumococci. Antimicrob Agents Chemother 1996; 40:2661-3.
5. Rubino CM, Van Wart SA, Bhavnani SM, Ambrose PG, McCollam JS, Forrest A. Oritavancin population pharmacokinetics in healthy subjects and patients with complicated skin and skin structure infections or bacteremia. Antimicrob Agents Chemother 2009; 53:1443-9.
6. Boylan CJ, Campanale K, Iversen PW, Phillips DL, Zeckel ML, Parr TR Jr. Pharmacodynamics of oritavancin (LY333328) in a neutropenicmouse thigh model of Staphylococcus aureus infection. Antimicrob Agents Chemother 2003; 47:1907-11.
7. Arhin FF, Sarmiento I, Belley A, et al. Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing. Antimicrob Agents Chemother 2008; 52:1597-603.
8. Belanger O, Rozborskaya O, Dietrich E, et al. 18th European Conference of Clinical Microbiology and Infectious Diseases. Hoboken, NJ: Wiley-Blackwell, 2008. Abstract P 1061.
9. Ahrin FF, Belley A, McKay G, et al. Assessment of oritavancin serum protein binding across species. Antimicrob Agents Chemother 2010; 54:3481-3.
10. Van Bambeke F, Carryn S, Seral C, et al. Cellular pharmacokinetics and pharmacodynamic of the glycopeptide antibiotic oritavancin (LY333328) in a model of J774 mouse macrophages. Antimicrob Agents Chemother 2004; 48:2853-60.
11. Bhavnani SM, Owen JS, Loutit JS, Porter SB, Ambrose PG. Pharmacokinetics, safety, and tolerability of ascending single intravenous doses of oritavancin administered to healthy human subjects. Diagn Microbiol Infect Dis 2004; 50:148-52.
12. Feeterly GJ, Ong CM, Bhavnani SM, et al. Pharmacokinetics of oritavancin in plasma and skin blister fluid following administration of a 200-milligram dose for 3 days or a single 800-milligram dose. Antimicrob Agents Chemother 2005; 49:148-52.
13. Lehoux D, Laquerre K, Ostiguy V, et al. A single 1200 mg human equivalent dose of oritavancin is highly efficacious in the neutropenic mouse thigh infection model [abstract P 1568]. In: 20th European Congress of Clinical Microbiology and Infectious Diseases. Hoboken, NJ: Wiley-Blackwell, 2010.
14. Knudsen JD, Raber S, Leggett J, Fuursted K, Espersen F, Fridmodt-Moller N. Comparison of effect of LY333328 with teicoplanin and vancomycin against pneumococci in mouse peritonitis model [abstract F-10]. In: 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997.
15. Rupp ME, Ulphani JS. Efficacy of LY333328 in a rat model of Staphylococcus aureus (SA) central venous catheter (CVC)-associated infection [abstract F-111]. In: 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998.
16. Kaatz GW, Seo SM, Aeschlimann JR, Houlihan HH, Mercier RC, Rybak MJ. Efficacy of LY33328 against experimental methicillinresistant Staphylococcus aureus endocarditis. Antimicrob Agents Chemother 1998; 42:981-3.
17. Xiong YQ, Yin L, Hady WA, et al. Efficacy of oritavancin (ORI), a lipoglycopeptide antibiotic, in a rat Staphylococcal aureus endocarditis (IE) model: microbiological and bioluminescent assessments [abstract B-1011]. In: 48th Interscience Conference on Antimicrobial Agents and Chemotherapy/Infectious Diseases Society of America 46th Annual Meeting. Washington, DC: American Society for Microbiology, 2008.
18. Saleh-Mghir A, Lefort A, Petegnief Y, et al. Activity and diffusion of LY333328 in experimental endocarditis due to vancomycin-resistant Enterococcus faecalis. Antimicrob Agents Chemother 1999; 43: 115-20.
19. Lefort A, Saleh-Mghir A, Garry L, Carbon C, Fantin B. Activity of LY333328 combined with gentamicin in vitro and in rabbit experimental endocarditis due to vancomycin-susceptible or-resistant Enterococcus faecalis. Antimicrob Agents Chemother 2000; 44:3017-21.
20. McKay GA, Beaulie S, Ahrin FF, et al. Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium. J Antimicrob Chemother 2009; 63:1191-9.
21. Lehoux D, Ostiguy V, Fadhil L, et al. Efficacy of oritavancin (ORI) in the mouse bacteremia model [abstract B-1009]. In: 48th Interscience Conference on Antimicrobial Agents and Chemotherapy/Infectious Diseases Society of America 46th Annual Meeting. Washington, DC: American Society for Microbiology, 2008.
22. Barcia-Macay M, Seral ß, Mineot-Leclercq MP, Tulkens PM, Van Bambeke F. Pharmacodynamic evaluation of the intracellular activities of antibiotics against Staphylococcus aureus in a model of THP-1 macrophages. Antimicrob Agents Chemother 2006; 50: 841-51.
23. Nguyen HA, Denis O, Vergison A, et al. Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype and revertant strains. Antimicrob Agents Chemother 2009; 53:1434-42.
24. Rupp ME, Fey PD, Longo GM. Effect of LY333328 against vancomycinresistant Enterococcus faecium in a rat central venous catheter-associated infection model. J Antimicrob Chemother 2001; 47:705-7.
25. Craig W, Andes D. Activity of oritavancin (O) versus vancomycin (V) in the neutropenic murine thigh-and lung-infection models [abstract A-1863]. In: 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 2004.
26. Lehoux D, McKay GA, Fadhil I, et al. Efficacy of oritavancin in a mouse model of Streptococcus pneumoniae pneumonia [abstract P-1781]. In: 17th European Conference of Clinical Microbiology and Infectious Diseases. Munich, Germany, 2007.
27. Ostiguy V, Fadhil I, Malouin M, et al. Efficacy of oritavancin in the rat haematogenous pneumonia model [abstract P1028]. In: 19th European Congress of Clinical Microbiology and Infectious Diseases. Helsinki, Finland, 2009.
28. Gerber J, Smirnov A, Wellmer A, et al. Activity of LU333328 in experimental meningitis caused by a Streptococcus pneumoniae strain susceptible to penicillin. Antimicrob Agents Chemother 2001; 45:1700-6.
29. Cabellos C, Fernàndez A, Maiques JM, et al. Experimental study of LY333328 (oritavancin), alone and in combination, in therapy of cephalosporin-resistant pneumococcal meningitis. Antimicrob Agents Chemother 2003; 47:1907-11.
30. Heine HS, Bassett J, Miller L, et al. Efficacy of oritavancin in a murine model of Bacillus anthracis spore inhalation anthrax. Antimicrob Agents Chemother 2008; 52:3350-7.
31. St-Denis B, Mong SM, Higgins M-E, Parr TR Jr, Lehoux D. Evaluation of different formulations of oritavancin in the hamster model of Clostridium difficile infection [abstract B-703]. In: 50th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 2010.
32. Fadhil I, Deng H, Rozborskaya O, et al. Evaluation of oritavancin efficacy and pharmacokinetic profile in the hamster model of Clostridium difficile infection [abstract P1562]. In: 20th European Congress of Clinical Microbiology and Infectious Disease. Washington, DC: American Society for Microbiology, 2010.
33. Baines SD, O'Connor R, Saxton K, Freeman J,WilcoxMH. Comparison of oritavancin versus vancomycin as treatments for clindamycin-induced Clostridium difficile PCR ribotype 027 infection in a human gut model. J Antimicrob Chemother 2008; 62:1078-85.
34. Ambrose PG, Bhavnani SM, Rubino CM, et al. Pharmacokineticspharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin Infect Dis 2007; 44:79-86.
35. Okusanya OO, Lehoux D, Van Wart SA, et al. Pharmacokinetics and pharmacokinetics-pharmacodynamics of oritavancin against Staphylococcus aureus using data from a neutropenic murine thighinfection model. In: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 2009.
36. Dunbar LM, Milata J, McClure T, Wasilewski MM. SIMPLIFI Study Team. Comparison of the efficacy and safety of oritavancin frontloaded dosing regimens to daily dosing: an analysis of the SIMPLIFI Trial. Antimicrob Agents Chemother 2011; 55:3476-84.